S
ample medications allow physicians to quickly initiate therapy to evaluate initial patient response. However, sample closets primarily contain newer, costly brand name medications and rarely have generic options available. Studies now suggest that sample availability may affect the medications that physicians choose to subsequently prescribe, 1, 2 but little data exist regarding this effect in private practice. In the present study, we explored the effect of removing samples of 3 medication classes on prescribing patterns at a private clinic.
Methods.
The primary objective of this study was to measure the effect of removing free samples of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins), levothyroxine products, and selective serotonin reuptake inhibitors (SSRIs) from a private clinic on the percentage of generic prescribing within each drug class and classes combined. Secondary objectives included the effect on generic prescribing for all medications and sustainability.
This was a 150-day pre-post study (60-day run-in, 90-day intervention) at Lakeview Internal Medicine in West Des Moines, Iowa. Prescribers participate in pay-forperformance and receive quarterly prescribing reports. Prior to the main intervention, all prescribers (n=5) attended an educational session presented by a clinical pharmacist reviewing current evidence on the study medication classes. Sample sign-out sheets were posted to demonstrate baseline sample use. All sampled statins, levothyroxine, and SSRIs were removed from the clinic for 90 days ( December 1, 2007 -February 28, 2008 . No restriction was placed on the ability to prescribe these medicines. Data from a third-party payer were used to compare generic prescribing percentage during the samplefree period and a matched 90-day period prior to intervention (July 2, 2007-September 29, 2007). Data were analyzed using 2 as a test of proportions. PϽ.05 was considered statistically significant.
Results. Six studied samples were removed from the clinic (3 statins, 2 levothyroxine products, and 1 SSRI Comment. To our knowledge, this is the first study that has successfully demonstrated increases in generic prescribing by removing select sample medications from a private practice setting. Previous studies have been conducted in health maintenance organizations or where hospital policies and formularies affect clinic prescribing.
2,3
Such interventions may not reflect the realities of private practice. Counter sampling has proven ineffective in private clinics. 4, 5 Our findings have implications for both patients and health care providers. Sample medication use has been shown to increase out-of-pocket costs for patients. 6 Thus, sample removal and provider education may help mitigate increasing health care expenditures. In addition, clinics participating in pay-for-performance agreements with insurance companies may benefit financially. Overall, generic prescribing increased from 58% to 65.1%. According to one third-party payer ("Incent and Reward Best Practices" [internal document, part of the Pay-forPerformance agreement between Wellmark and the clinic physicians], January 2008), this clinic moved from not qualifying for a generic prescribing award to the highest level award offered in 180 days. Further study of the financial implications of sample removal from this setting should be considered. 
